Department of GlobalHealth, University of Amsterdam, Amsterdam, The Netherlands.
J Infect Dis. 2012 Jun;205(11):1739-44. doi: 10.1093/infdis/jis261. Epub 2012 Mar 23.
Little is known about the effect of human immunodeficiency virus type 1 (HIV-1) resistance mutations present at time of regimen switch on the response to second-line antiretroviral therapy in Africa. In adults who switched to boosted protease inhibitor-based regimens after first-line failure, HIV-RNA and genotypic resistance testing was performed at switch and after 12 months. Factors associated with treatment failure were assessed using logistic regression. Of 243 participants, 53% were predicted to receive partially active second-line regimens due to drug resistance. The risk of treatment failure was, however, not increased in these participants. In this African cohort, boosted protease inhibitors successfully resuppressed drug-resistant HIV after first-line failure.
目前对于方案转换时存在的人类免疫缺陷病毒 1 型（HIV-1）耐药突变对非洲二线抗逆转录病毒治疗反应的影响知之甚少。在一线治疗失败后转换为增效蛋白酶抑制剂为基础方案的成年人中，在转换时和 12 个月时进行 HIV-RNA 和基因型耐药性检测。使用逻辑回归评估与治疗失败相关的因素。在 243 名参与者中，由于耐药性，53%的人预计将接受部分有效的二线治疗方案。然而，这些参与者的治疗失败风险并未增加。在这个非洲队列中，增效蛋白酶抑制剂在一线治疗失败后成功地抑制了耐药性 HIV。
